AR119942A1 - Tratamiento de hidradenitis con inhibidores de quinasa - Google Patents

Tratamiento de hidradenitis con inhibidores de quinasa

Info

Publication number
AR119942A1
AR119942A1 ARP200102525A ARP200102525A AR119942A1 AR 119942 A1 AR119942 A1 AR 119942A1 AR P200102525 A ARP200102525 A AR P200102525A AR P200102525 A ARP200102525 A AR P200102525A AR 119942 A1 AR119942 A1 AR 119942A1
Authority
AR
Argentina
Prior art keywords
methyl
pharmaceutically acceptable
acceptable salt
hidradenitis
treatment
Prior art date
Application number
ARP200102525A
Other languages
English (en)
Inventor
Andrew Fensome
Brian Stephen Gerstenberger
Dafydd Rhys Owen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR119942A1 publication Critical patent/AR119942A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Abstract

Métodos para tratar hidradenitis supurativa usando compuestos y análogos que inhiben determinadas quinasas, que incluyen la quinasa Janus (JAK). Reivindicación 2: El método de acuerdo con la reivindicación 1, caracterizado porque dicho inhibidor de Tyk2 / JAK1 es [(1S)-2,2-difluorociclo-propil][(1R,5S)-3-{2-[(1-metil-1H-pirazol-4-il)amino]pirimidin-4-il}-3,8-diazabiciclo[3.2.1]oct-8-il]metanona; o una sal de aquel aceptable desde el punto de vista farmacéutico. Reivindicación 5: El método de acuerdo con la reivindicación 1, caracterizado porque dicho inhibidor de JAK1 es N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}-propan-1-sulfonamida, o una sal de aquel aceptable desde el punto de vista farmacéutico. Reivindicación 6: El método de acuerdo con la reivindicación 1, caracterizado porque dicho inhibidor de Tyk2 es (1r,3r)-3-(cianometil)-3-(4-(6-(1-metil-1H-pirazol-4-il)pirazolo[1,5-a]pirazin-4-il)-1H-pirazol-1-il)ciclobutan-1-carbonitrilo, o una sal de aquel aceptable desde el punto de vista farmacéutico.
ARP200102525A 2019-09-11 2020-09-11 Tratamiento de hidradenitis con inhibidores de quinasa AR119942A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962899133P 2019-09-11 2019-09-11

Publications (1)

Publication Number Publication Date
AR119942A1 true AR119942A1 (es) 2022-01-19

Family

ID=72473596

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102525A AR119942A1 (es) 2019-09-11 2020-09-11 Tratamiento de hidradenitis con inhibidores de quinasa

Country Status (12)

Country Link
EP (1) EP4028007A1 (es)
JP (1) JP2021042204A (es)
KR (1) KR20220059519A (es)
CN (1) CN114667148A (es)
AR (1) AR119942A1 (es)
AU (1) AU2020347561A1 (es)
BR (1) BR112022004221A2 (es)
CA (1) CA3153676A1 (es)
IL (1) IL291146A (es)
MX (1) MX2022002995A (es)
TW (1) TW202123940A (es)
WO (1) WO2021048736A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230293544A1 (en) * 2022-03-17 2023-09-21 Pfizer Inc. Methods, dosage regimens, and compositions for treating hidradenitis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2958921T3 (da) * 2013-02-22 2017-11-06 Pfizer Pyrrolo[2,3-D]pyrimidin-derivater som hæmmere af Janus kinaser (JAK)
NO2721710T3 (es) * 2014-08-21 2018-03-31
WO2017143014A1 (en) * 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
NZ744349A (en) 2016-02-24 2023-06-30 Pfizer Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EP3848370A3 (en) * 2016-10-14 2021-09-15 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
MA52655A (fr) * 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
MX2022012285A (es) * 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).

Also Published As

Publication number Publication date
IL291146A (en) 2022-05-01
AU2020347561A1 (en) 2022-04-14
TW202123940A (zh) 2021-07-01
KR20220059519A (ko) 2022-05-10
CA3153676A1 (en) 2021-03-18
JP2021042204A (ja) 2021-03-18
CN114667148A (zh) 2022-06-24
WO2021048736A1 (en) 2021-03-18
MX2022002995A (es) 2022-06-02
BR112022004221A2 (pt) 2022-05-31
EP4028007A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
HRP20201887T1 (hr) LIJEČENJE B-STANIČNIH MALIGNITETA S KOMBINACIJOM INHIBITORA JAK i PI3K
ZA201808534B (en) Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide
HRP20180746T4 (hr) Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze
JP2020504136A5 (es)
CL2008001364A1 (es) Uso de compuestos derivados de imidazol(1,2-b) piridazina y pirazolo(1,5-a) pirimidina inhibidores de tirosina quinasa pi-para tratar tumor benigno o maligno, entre otros; compuestos dereivados de imidazol(1,2-b)piridazina y pirazolo(1,5-a)pirimidina; composiciones farmaceuticas; y metodo de preparacion de compuestos.
HRP20170090T1 (hr) Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
AU2015364335A1 (en) Treatment of pemphigus
EA201070013A1 (ru) СОЛИ ИНГИБИТОРА ЯНУС-КИНАЗЫ (R)-3-(4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
NZ611151A (en) Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
HRP20150987T1 (hr) UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
RU2014115476A (ru) Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ
RU2009140469A (ru) Производные пирролопиримидин-7-она и их применение в качестве фармацевтических средств
AR067024A1 (es) Metabolitos del inhibidor de janus quinasa (r)-3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo
PE20212186A1 (es) Inhibidores de la via de jak1 para el tratamiento de trastornos relacionados con citoquinas
SA520412192B1 (ar) مشتقات 5-(2-(2، 5-داي فلورو فنيل)بيروليدين-1-يل) -3-(1h-بيرازول-1-يل) بيرازولو[1، 5-a] بيريميدين والمركبات ذات الصلة كمثبطات كيناز trk لعلاج السرطان
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MX2020010675A (es) Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina.
EA202191903A1 (ru) Антипролиферативные соединения и вторые активные агенты для комбинированного применения
AR119942A1 (es) Tratamiento de hidradenitis con inhibidores de quinasa
PH12020551638A1 (en) Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
NZ703152A (en) Dosing regimen for janus kinase (jak) inhibitors
UY31866A (es) Combinaciones farmacéuticas comprendiendo los compuestos 3-z[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilene]-6-metoxicarbonil-2-indolinona y el ácido n-[4-[2-(2-amino-4,7-dihidro-4-oxo-1h-pirrolo [2,3-d] pirimidin-5-il)etil]benzoil]-l-glutamico; sus sales farmacéuticamente aceptables y aplicaciones
AR119210A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
AR120809A1 (es) Tratamiento de colitis ulcerosa con inhibidores de quinasa